US2002119202A1PendingUtilityA1

Anti-angiogenic compositions and methods of use

53
Priority: Jul 19, 1993Filed: Aug 9, 2001Published: Aug 29, 2002
Est. expiryJul 19, 2013(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay MachanA. ArsenaultHelen BurtJohn JacksonStephen Dordunoo
A61P 35/00A61P 43/00A61P 7/02A61P 9/10A61P 9/14A61P 9/00A61P 7/04A61P 27/02A61P 19/02A61P 1/04A61P 11/00A61P 13/02A61P 1/16A61K 9/1641A61K 33/00A61K 31/335A61K 31/427A61K 31/702A61K 9/0019A61K 31/426A61K 33/06A61K 31/555A61K 31/565A61L 2300/416C08L 2203/02A61K 31/4745A61K 31/337A61K 31/525A61K 9/5153C08L 29/04A61K 31/136C08L 2312/00Y10S977/773A61K 9/1647A61L 31/10A61K 31/122A61L 2300/622A61K 31/519A61K 9/1658C07C 233/64A61K 9/1635A61K 31/57C08L 67/04A61L 31/145C07K 14/811C08L 23/0853A61K 9/7007A61K 9/5031A61K 9/0048A61K 9/0051A61K 33/30A61K 9/5146A61K 38/57A61L 31/16A61L 2430/36A61L 2300/606A61K 45/06A61K 31/203Y10S977/915A61K 9/14A61K 31/185B82Y 5/00A61K 31/165A61K 31/20A61K 33/24
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A composition, comprising: 
 (a) a compound which disrupts microtubule function; and    (b) a polymeric carrier, with the proviso that said polymeric carrier is not a capsule.    
     
     
         2 . The composition according to  claim 1  wherein said composition is formed into microspheres having an average size of between 0.5 and 200 μm.  
     
     
         3 . The composition according to  claim 1  wherein said composition is formed into a film with a thickness of between 100 μm and 2 mm.  
     
     
         4 . The composition according to  claim 1  wherein said composition is liquid above 45° C., and solid or semi-solid at 37° C.  
     
     
         5 . The composition according to  claim 1  wherein said polymeric carrier is poly(ethylene-vinyl acetate) (40% crosslinked).  
     
     
         6 . The composition according to  claim 1  wherein said polymeric carrier is copolymer of lactic acid and glycolic acid.  
     
     
         7 . The composition according to  claim 1  wherein said polymeric carrier is poly (caprolactone).  
     
     
         8 . The composition according to  claim 1  wherein said polymeric carrier is poly (lactic acid).  
     
     
         9 . The composition according to  claim 1  wherein said polymeric carrier is a copolymer of poly (lactic acid) and poly (caprolactone).  
     
     
         10 . The composition according to  claim 1  wherein said compound which disrupts microtubule function is paclitaxel.  
     
     
         11 . The composition according to  claim 1  wherein said compound which disrupts microtubule function is selected from the group consisting of estramustine, colchicine, methotrexate, curacin-A, epothilone, vinblastine and tBCEU.

Join the waitlist — get patent alerts

Track US2002119202A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.